» Articles » PMID: 10904089

Familial Risk of Hepatocellular Carcinoma Among Chronic Hepatitis B Carriers and Their Relatives

Overview
Specialty Oncology
Date 2000 Jul 25
PMID 10904089
Citations 63
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Familial predisposition as a risk factor for hepatocellular carcinoma (HCC) in hepatitis B virus (HBV) carriers has not been thoroughly explored.

Methods: The HCC risk associated with having parents and/or siblings with HCC was evaluated by use of a cohort study of 4808 male HBV carriers. A case-control family study was also conducted on data from first-degree relatives of 553 HBV carriers who had newly diagnosed HCC (case subjects) and 4684 HBV carriers without HCC (control subjects).

Results: In the cohort study, HBV carriers with a family history of HCC had a multivariate-adjusted rate ratio for HCC of 2.41 (95% confidence interval [CI] = 1.47-3.95) compared with HBV carriers without a family history of HCC. For carriers with two or more affected relatives, the ratio increased to 5.55 (95% CI = 2.02-15.26). Cumulative HCC risk by age 70 years was 235.6 per 1000 (95% CI = 95. 3-375.9 per 1000) for HBV carriers with family history compared with 88.9 per 1000 (95% CI = 67.9-109.9 per 1000) for those without. In the case-control family study, first-degree relatives of case subjects were more likely to have HCC (age-sex-adjusted odds ratio [OR] = 2.57; 95% CI = 2.03-3.25) than first-degree relatives of control subjects. The excess risk of HCC among relatives was particularly evident in siblings (sisters-age-adjusted OR = 4.55 [95% CI = 2.22-9.31]; brothers-age-adjusted OR = 3.73 [95% CI = 2. 64-5.27]), but it was also observed in parents. The cumulative risk of HCC to age 80 years was 83.0 per 1000 among relatives of case subjects and 42.0 per 1000 among relatives of control subjects. Among relatives of case subjects, the cumulative risk of HCC was greater if the case subjects were diagnosed before age 50 years (two-sided P =.047). Liver cirrhosis was 2.29 (95% CI = 1.68-3.11) times more frequent in relatives of case subjects than in relatives of control subjects.

Conclusions: First-degree relatives of patients with HBV-related HCC appear to be at increased risk of HCC and should be considered in the formulation of HCC-screening programs.

Citing Articles

Dynamic Changes of Growth and Thyroid Function in Young Children With Chronic Hepatitis B Treated With Peginterferon Monotherapy.

He Q, Mao C, Chen Z, Duan F, Huang L, Hu R Pediatr Infect Dis J. 2024; 44(2):112-117.

PMID: 39348504 PMC: 11731032. DOI: 10.1097/INF.0000000000004567.


Genetic screening of liver cancer: State of the art.

Peruhova M, Banova-Chakarova S, Miteva D, Velikova T World J Hepatol. 2024; 16(5):716-730.

PMID: 38818292 PMC: 11135278. DOI: 10.4254/wjh.v16.i5.716.


Genetic Susceptibility to Hepatocellular Carcinoma in Patients with Chronic Hepatitis Virus Infection.

Yang T, Chan C, Yang P, Huang Y, Lee M Viruses. 2023; 15(2).

PMID: 36851773 PMC: 9964813. DOI: 10.3390/v15020559.


Management of Hepatitis B Virus Infection: 2018 Guidelines from the Canadian Association for the Study of Liver Disease and Association of Medical Microbiology and Infectious Disease Canada.

Coffin C, Fung S, Alvarez F, Cooper C, Doucette K, Fournier C Can Liver J. 2022; 1(4):156-217.

PMID: 35992619 PMC: 9202759. DOI: 10.3138/canlivj.2018-0008.


Hepatitis B: Who should be treated?-managing patients with chronic hepatitis B during the immune-tolerant and immunoactive phases.

Kawanaka M, Nishino K, Kawamoto H, Haruma K World J Gastroenterol. 2021; 27(43):7497-7508.

PMID: 34887645 PMC: 8613739. DOI: 10.3748/wjg.v27.i43.7497.